Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBIT (2016 - 2025)

Historic EBIT for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$35.6 million.

  • Sangamo Therapeutics' EBIT fell 43442.76% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.0 million, marking a year-over-year increase of 2214.54%. This contributed to the annual value of -$104.0 million for FY2024, which is 6205.58% up from last year.
  • Latest data reveals that Sangamo Therapeutics reported EBIT of -$35.6 million as of Q3 2025, which was down 43442.76% from -$17.9 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' EBIT ranged from a high of $18.0 million in Q1 2023 and a low of -$123.6 million during Q2 2023
  • Its 5-year average for EBIT is -$44.5 million, with a median of -$45.7 million in 2022.
  • As far as peak fluctuations go, Sangamo Therapeutics' EBIT plummeted by 120872.74% in 2021, and later soared by 13984.45% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' EBIT stood at -$39.9 million in 2021, then plummeted by 38.83% to -$55.4 million in 2022, then dropped by 12.04% to -$62.1 million in 2023, then skyrocketed by 58.12% to -$26.0 million in 2024, then crashed by 36.79% to -$35.6 million in 2025.
  • Its EBIT was -$35.6 million in Q3 2025, compared to -$17.9 million in Q2 2025 and -$29.6 million in Q1 2025.